CryoLife sees record performance in Q3 2010

CryoLife has published its financial report for the three-month period ending on September 30th 2010, during which it achieved its best-ever third quarter results.

The medical device manufacturer saw a one percent year-on-year increase in revenue to achieve a record total of $28.4 million (17.6 million pounds), while its nine-month figure now stands at a benchmark $87.4 million.

During the last three months, the company was able to obtain Japanese regulatory approval for its BioGlue product, while also gaining distribution and marketing rights to the haemostatic agent PerClot.

The latter offering made its European market debut in France last month ahead of a planned continent-wide rollout over the coming months.

Steven Anderson, president and chief executive officer at CryoLife, expressed confidence that it will be able to continue delivering value for its shareholders.

He added: "With our continued strong cash flow generation we are well-positioned to pursue business development opportunities that will expand our product offerings to surgeons and patients worldwide."